CURRENT
ISSUE
1585
November 18, 2019

Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.1,2

THC — In the US, 33 states and the District of Columbia now permit some medical use of marijuana (Cannabis sativa).3 In these states, cannabis products are available with varying restrictions and requirements, such as a certification for each...  Continue reading

More from Issue 1585
Previous Issue: 1584      November 4, 2019
Coming Soon
Trifarotene (Aklief) - A New Topical Retinoid for Acne
Brolucizumab (Beovu) for Age-Related Macular Degeneration
Drugs for Some Common Eye Disorders
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
Letermovir (Prevymis) for CMV Prophylaxis
Search
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
 Tweets
FROM
ISSUE
1585

The FDA has approved upadacitinib (Rinvoq – Abbvie), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to or cannot tolerate methotrexate (Trexall, and others). Upadacitinib is the third JAK inhibitor to be approved in the US for treatment of RA; tofacitinib (Xeljanz, Xeljanz XR) and baricitinib (Olumiant) were approved earlier.1,2

STANDARD TREATMENT — For ... Continue reading